125 related articles for article (PubMed ID: 15981668)
21. Who wants cancer screening with PET? A contingent valuation survey in Japan.
Yasunaga H
Eur J Radiol; 2009 Apr; 70(1):190-4. PubMed ID: 18093777
[TBL] [Abstract][Full Text] [Related]
22. Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report.
Nishizawa S; Kojima S; Teramukai S; Inubushi M; Kodama H; Maeda Y; Okada H; Zhou B; Nagai Y; Fukushima M
J Clin Oncol; 2009 Apr; 27(11):1767-73. PubMed ID: 19255324
[TBL] [Abstract][Full Text] [Related]
23. PET/CT and breast cancer.
Zangheri B; Messa C; Picchio M; Gianolli L; Landoni C; Fazio F
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S135-42. PubMed ID: 15133636
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
25. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer.
Chang MC; Chen JH; Liang JA; Lin CC; Yang KT; Cheng KY; Yeh JJ; Kao CH
Acad Radiol; 2012 Mar; 19(3):349-57. PubMed ID: 22173321
[TBL] [Abstract][Full Text] [Related]
26. [Cancer screening with PET: advantages and limitations].
Kawada S; Suzuki Y; Hinohara S; Koide S; Ono Y; Ashikaga H
Rinsho Byori; 2007 Jul; 55(7):656-67. PubMed ID: 17718062
[TBL] [Abstract][Full Text] [Related]
27. Clinically unrecognized pulmonary aspiration during gastrointestinal endoscopy with sedation: a potential pitfall interfering the performance of 18F-FDG PET for cancer screening.
Hsieh TC; Wu YC; Ding HJ; Wang CH; Yen KY; Sun SS; Yeh JJ; Kao CH
Eur J Radiol; 2011 Dec; 80(3):e510-5. PubMed ID: 21439750
[TBL] [Abstract][Full Text] [Related]
28. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.
van der Veldt AA; Buist MR; van Baal MW; Comans EF; Hoekstra OS; Molthoff CF
J Nucl Med; 2008 Dec; 49(12):1936-43. PubMed ID: 18997039
[TBL] [Abstract][Full Text] [Related]
29. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
30. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
[TBL] [Abstract][Full Text] [Related]
31. The value of 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening.
Shen YY; Su CT; Chen GJ; Chen YK; Liao AC; Tsai FS
Neoplasma; 2003; 50(3):217-21. PubMed ID: 12937856
[TBL] [Abstract][Full Text] [Related]
32. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
33. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?
Zoller M; Kohlfuerst S; Igerc I; Kresnik E; Gallowitsch HJ; Gomez I; Lind P
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):487-95. PubMed ID: 17103166
[TBL] [Abstract][Full Text] [Related]
34. Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care.
Israel O; Kuten A
J Nucl Med; 2007 Jan; 48 Suppl 1():28S-35S. PubMed ID: 17204718
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of both PET/CT with F18-FDG and whole-body diffusion-weighted imaging in cancer screening: a preliminary report.
Sasamori H; Uno K; Wu J
Ann Nucl Med; 2019 Feb; 33(2):78-85. PubMed ID: 30298377
[TBL] [Abstract][Full Text] [Related]
36. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence.
Metser U; Miller E; Lerman H; Even-Sapir E
AJR Am J Roentgenol; 2007 Nov; 189(5):1203-10. PubMed ID: 17954662
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and diagnostic accuracy of [18F]FDG-PET/CT in 190 patients with carcinoma of unknown primary.
Fencl P; Belohlavek O; Skopalova M; Jaruskova M; Kantorova I; Simonova K
Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1783-92. PubMed ID: 17541584
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study.
Cheze-Le Rest C; Metges JP; Teyton P; Jestin-Le Tallec V; Lozac'h P; Volant A; Visvikis D
Nucl Med Commun; 2008 Jul; 29(7):628-35. PubMed ID: 18528185
[TBL] [Abstract][Full Text] [Related]
39. Positron emission tomography in gynecologic cancer.
Yen TC; Lai CH
Semin Nucl Med; 2006 Jan; 36(1):93-104. PubMed ID: 16356798
[TBL] [Abstract][Full Text] [Related]
40. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
